Fig. 5: Efficacy of SOF10 (mFc) combined with an anti-PD-L1 in an EMT6 immune-excluded tumor model.

a Efficacy of SOF10 (mFc) combined with anti-PD-L1 in an EMT6 mouse model. Mice with EMT6 cell-derived tumors were treated with an isotype control, SOF10 (mFc), GC1008 (mFc) and/or an anti-PD-L1 3 times per week for 2 weeks. The tumor volume was evaluated on day 14 after treatment initiation (N = 10). For multiple group comparisons, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, and ^****P < 0.0001 according to Dunnett test. b RNA expression in EMT6 tumors was measured via an nCounter Analysis System. RNA was extracted from treated tumors on day 14 after treatment initiation. The heatmap shows the normalized expression values (Z-scores) of selected genes. The boxplots show the log2 normalized counts. The center represents the median; bounds show the 25% and 75% percentiles; and whiskers extend to the most extreme data points within 1.5× the interquartile range from the quartiles. For multigroup comparisons, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, and ^****P < 0.0001 according to Tukey’s test. c The numbers of CD8 + T cells and granzyme B + CD8 + T cells in the tumors were analyzed by flow cytometry on day 9 after treatment initiation (N = 5). For multigroup comparisons, ^*P < 0.05, and ^**P < 0.01 according to Dunnett’s test. d Signature scores of CAFs isolated from treated tumors 10 days after treatment initiation. In box plots, the center represents the median; bounds show the 25% and 75% percentiles; and whiskers extend to the most extreme data points within 1.5× the interquartile range from the quartiles. For multigroup comparisons, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, and ^****P < 0.0001 according to Tukey’s test.